Stockscreener 앱 받기
13.13
0.15%
0.02
시간 외 거래:
13.21
0.08
+0.61%
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring a Potential 379% Upside in Biotech Innovations - DirectorsTalk Interviews
What is Janux Therapeutics Inc.’s valuation compared to sectorEarnings Overview Summary & Fast Momentum Entry Tips - mfd.ru
Breakout Watch: What is Janux Therapeutics Incs debt to equity ratioDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Bristol Myers Squibb Expands RNA And Cell Therapy Pipeline As Valuation Lags - Yahoo! Finance Canada
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowShould You Sell? - MarketBeat
Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN
(JANX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High? - Yahoo Finance UK
Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007 - Insider Monkey
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) - Yahoo Finance
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bristol-Myers Squibb Expands Cancer Efforts With New AI And Drug Deals - Yahoo Finance UK
Why is Janux Therapeutics Inc. stock going downPortfolio Value Report & Weekly High Conviction Trade Ideas - mfd.ru
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Janux Therapeutics Repeat Insider Selling Not A Positive Indicator - simplywall.st
Eikon Therapeutics targets $908 million valuation in US IPO - Yahoo Finance
Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy - Yahoo Finance
Janux Therapeutics appoints William Go as new chief medical officer By Investing.com - Investing.com Nigeria
Janux Therapeutics (NASDAQ:JANX) Shares Gap DownShould You Sell? - MarketBeat
Janux Therapeutics Taps Dr. William Go as Chief Medical Officer - Contract Pharma
Janux Therapeutics appoints William Go as new chief medical officer - Investing.com
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - ChartMill
Bristol Myers inks licensing deal with Janux for cancer therapy - MSN
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion (BMY) - Seeking Alpha
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100 - 富途牛牛
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results - Yahoo Finance
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - ET Pharma
Janux Therapeutics Inks Global Oncology Collaboration With BMS - TipRanks
Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb - TradingView
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeHere's Why - MarketBeat
Janux Therapeutics Pairs With BMS on Novel Tumor-Activated Therapeutic - Contract Pharma
Key facts: Bristol Myers Squibb signs $850M deal with Janux; partners with Microsoft for AI - TradingView
BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy - MedCity News
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
BMS bets on Janux’s novel solid tumour therapy through $850m deal - Yahoo Finance
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors - marketscreener.com
Bristol Myers buys into Janux’s ‘masked’ T cell engagers - BioPharma Dive
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com Canada
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - BioSpace
Janux stock rises after Bristol Myers Squibb collaboration deal By Investing.com - Investing.com UK
Janux stock rises after Bristol Myers Squibb collaboration deal - Investing.com
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million - Intellectia AI
Bristol Myers (BMY) Partners with Janux Therapeutics on Cancer T - GuruFocus
1.24%
0.19%
자본화:
|
볼륨(24시간):